The Dual Role of the Gut Microbiota in Cancer Chemoresistance
MicrobiologyOpen · 2026-08 · 15 (4)
DOI: 10.1002/mbo3.70357 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift MicrobiologyOpen, online erschienen am 08.07.2026. Verfasst von Hamed Tahmasebi und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Neoplasms, Gastrointestinal Microbiome, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 151 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chemoresistance is one of the primary reasons that cancer chemotherapy fails to deliver successful treatment outcomes and contributes to poor overall survival rates for patients with cancer. New research has begun to shed light on the effects of the gut microbiome (GM). This new research will examine how certain microorganisms (referred to as “bad bacteria”) can contribute to cancer treatment failure, as well as how others (such as Bifidobacterium , Akkermansia , and Lactobacillus ) can enhance treatment success. This review will focus on the molecular mechanisms underlying these effects, including drug metabolism by microorganisms, modulation of the immune system by microorganisms, regulation of cellular apoptosis by microorganisms, and metabolic crosstalk between tumor tissue and the microbiome. Finally, we will look at new therapies under development that leverage knowledge of the microbiome to combat chemoresistance, including fecal microbiota transplantation, targeted probiotic and prebiotic supplementation, and dietary modifications. By studying the complex interactions among the host, the microbiome, and chemotherapeutic agents, we hope to demonstrate how microbiome‐centered approaches can tailor and enhance an individual's cancer treatment while transforming the GM from a passive participant to an active target in cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran.
- Department of Bacteriology, Pasteur Institute of Iran, Tehran, Iran.
- Biochemistry Department, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
- Department of Microbiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
- Nutrition Health Research Center, Institute of Health Sciences and Technologies, Hamadan University of Medical Sciences, Hamadan, Iran.
ORCID-Profile: Hamed Tahmasebi, Aisa Bahar, Meisam Khazaei, Mohammad Reza Arabestani
Zitieren
APA
Tahmasebi, H., Bahar, A., Khazaei, M., & Arabestani, M. R. (2026). The Dual Role of the Gut Microbiota in Cancer Chemoresistance. MicrobiologyOpen, 15(4). https://doi.org/10.1002/mbo3.70357
Vancouver
Tahmasebi H, Bahar A, Khazaei M, Arabestani MR. The Dual Role of the Gut Microbiota in Cancer Chemoresistance. MicrobiologyOpen. 2026;15(4). doi:10.1002/mbo3.70357
BibTeX
@article{Tahmasebi2026,
author = {Tahmasebi, Hamed and Bahar, Aisa and Khazaei, Meisam and Arabestani, Mohammad Reza},
title = {The Dual Role of the Gut Microbiota in Cancer Chemoresistance},
journal = {MicrobiologyOpen},
year = {2026},
volume = {15},
number = {4},
doi = {10.1002/mbo3.70357}
}
EUVIMED